A 12‐week DBPC dose‐finding study with sublingual monomeric allergoid tablets in house dust mite‐allergic patients

BACKGROUND: In sublingual immunotherapy, optimal doses are a key factor for therapeutic outcomes. The aim of this study with tablets containing carbamylated monomeric house dust mite allergoids was to determine the most effective and safe dose. METHODS: In this double‐blind, placebo‐controlled dose‐...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Allergy
Päätekijät: Hüser, C., Dieterich, P., Singh, J., Shah‐Hosseini, K., Allekotte, S., Lehmacher, W., Compalati, E., Mösges, R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
ORIGINAL ARTICLES
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217067/
https://ncbi.nlm.nih.gov/pubmed/27068870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.12913
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia